Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4251466 | 0.99 | DRD2 (0.44) | DRD2DRD3HTR1AHTR2AHRH1 | |
| SCHEMBL13806085 | 0.91 | SLC6A2 (0.42) | DRD2DRD3HTR1AHTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL4551186 | 0.90 | SLC6A2 (0.42) | DRD2DRD3HTR1AHTR2ASLC6A2 | |
| SCHEMBL27773178 | 0.89 | DRD2 (0.43) | DRD2DRD3HTR1AHTR2AHRH1 | |
| SCHEMBL13806211 | 0.89 | DRD2 (0.42) | DRD2DRD3HTR1AHTR2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4853288 | 0.88 | DRD2 (0.42) | DRD2DRD3HTR1AHTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL4256122 | 0.88 | DRD2 (0.42) | DRD2DRD3HTR1AHTR2ASLC6A2 | |
| SCHEMBL13806191 | 0.87 | DRD2 (0.39) | DRD2DRD3HRH1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4252095 | 0.86 | DRD2 (0.38) | DRD2DRD3HTR1AHTR2AHRH1 | |
| SCHEMBL27671014 | 0.86 | DRD2 (0.46) | DRD2DRD3HTR1AHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | CCR10, H1-10, VCAM1 | DRD2 746/4885DRD3 638/4885HTR1A 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.